Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Andrew Mark Brunner, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. El-Jawahri A, Luskin MR, Greer JA, Traeger L, Lavoie M, Vaughn DM, Andrews S, Yang D, Boateng KY, Newcomb RA, Ufere NN, Fathi AT, Hobbs G, Brunner A, Abel GA, Stone RM, DeAngelo DJ, Wadleigh M, Temel JS. Psychological mobile app for patients with acute myeloid leukemia (AML): A pilot randomized clinical trial. Cancer. 2023 Jan 18. PMID: 36655338.
    Citations:    Fields:    
  2. Lesegretain A, Brunner A, King AJ, Laadem A, Fell G, Fathi AT. Comparison of demographics, disease characteristics, and outcomes between Black and White patients with myelodysplastic syndromes: A population-based study. Leuk Res. 2022 Dec 26; 125:107006. PMID: 36580877.
    Citations:    Fields:    
  3. Brunner AM, Leitch HA, van de Loosdrecht AA, Bonadies N. Management of patients with lower-risk myelodysplastic syndromes. Blood Cancer J. 2022 12 14; 12(12):166. PMID: 36517487; PMCID: PMC9751093.
    Citations:    Fields:    Translation:Humans
  4. Shimony S, Liu Y, Valtis YK, Paolino JD, Place AE, Brunner AM, Weeks LD, Silverman LB, Vrooman LM, Neuberg D, Stone RM, DeAngelo DJ, Luskin MR. Nelarabine Combination Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Lymphoma/Leukemia. Blood Adv. 2022 Dec 12. PMID: 36508268.
    Citations:    Fields:    
  5. Aubrey BJ, Brunner A. Evidence-Based Minireview: Clinical utilization of panel-based molecular testing for patients with AML. Hematology Am Soc Hematol Educ Program. 2022 12 09; 2022(1):30-33. PMID: 36485121; PMCID: PMC9820249.
    Citations:    Fields:    Translation:Humans
  6. DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, Bejanyan N, Atallah E, Tamari R, Solh MM, Percival ME, de Lima M, Scott B, Oran B, Garcia-Manero G, Hamadani M, Carpenter P, DeZern AE. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transplant Cell Ther. 2022 Nov 25. PMID: 36436780.
    Citations:    Fields:    
  7. Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, Mims AS, DeFilipp Z, El-Jawahri A, McAfee SL, Brunner AM, Narayan R, Knight LW, Kelley D, Bottoms AS, Perry LH, Wahl JL, Brock J, Breton E, Ho VT, Chen YB. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv. 2022 11 22; 6(22):5857-5865. PMID: 36150050; PMCID: PMC9649991.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  8. Brunner AM, Gavralidis A, Ali NA, Hunter A, Komrokji R, Zeidan A, Sallman DA. Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS). Blood Cancer J. 2022 11 15; 12(11):153. PMID: 36379923; PMCID: PMC9666661.
    Citations:    Fields:    Translation:Humans
  9. Zeidan AM, Borate U, Pollyea DA, Brunner AM, Roncolato F, Garcia JS, Filshie R, Odenike O, Watson AM, Krishnadasan R, Bajel A, Naqvi K, Zha J, Cheng WH, Zhou Y, Hoffman D, Harb JG, Potluri J, Garcia-Manero G. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023 Feb; 98(2):272-281. PMID: 36309981.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  10. Garcia JS, Flamand Y, Penter L, Keng M, Tomlinson B, Mendez LM, Koller PB, Cullen N, Arihara Y, Pfaff KL, Wolff JO, Brunner AM, Galinsky I, Bashey A, Antin JH, Cutler CS, Ho VT, Jonas BA, Luskin MR, Wadleigh M, Winer ES, Savell A, Leonard R, Robertson T, Davids MS, Streicher H, Rodig SJ, Ritz J, Wu CJ, DeAngelo DJ, Neuberg D, Stone RM, Soiffer RJ. Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings. Blood. 2022 Nov 04. PMID: 36332187.
    Citations:    Fields:    
  11. Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia. 2022 12; 36(12):2939-2946. PMID: 36266326.
    Citations:    Fields:    Translation:Humans
  12. Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski DT, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore SD, List AF, Kuchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). Blood Adv. 2022 Oct 19. PMID: 36260702.
    Citations:    Fields:    
  13. Amonoo HL, Daskalakis E, Deary EC, Bodd MH, Reynolds MJ, Nelson AM, Newcomb R, Dhawale TM, Yang D, Luger SM, Gustin JL, Brunner A, Fathi AT, LeBlanc TW, El-Jawahri A. Relationship Between Longitudinal Coping Strategies and Outcomes in Patients With Acute Myeloid Leukemia. J Natl Compr Canc Netw. 2022 10; 20(10):1116-1123. PMID: 36240844.
    Citations:    Fields:    Translation:Humans
  14. Kayser S, Sartor C, Luskin MR, Webster J, Giglio F, Panitz N, Brunner AM, Fante M, Lutz C, Wolff D, Ho AD, Levis MJ, Schlenk RF, Papayannidis C. Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin. Haematologica. 2022 09 01; 107(9):2064-2071. PMID: 35142153; PMCID: PMC9425305.
    Citations:    Fields:    
  15. Fitzpatrick MJ, Boiocchi L, Fathi AT, Brunner AM, Hasserjian RP, Nardi V. Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia. Histopathology. 2022 Oct; 81(4):496-510. PMID: 35869818.
    Citations:    Fields:    
  16. Aubrey BJ, Brunner AM. SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2022 Dec; 22(12):869-877. PMID: 36030175.
    Citations:    Fields:    Translation:Humans
  17. Brunner AM, Fell G, Steensma DP. Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"? Blood Adv. 2022 05 10; 6(9):2854-2866. PMID: 35143613; PMCID: PMC9092413.
    Citations:    Fields:    Translation:Humans
  18. Amonoo HL, Bodd MH, Reynolds MJ, Nelson AM, Newcomb R, Johnson PC, Dhawale TM, Plotke R, Heuer L, Gillani S, Yang D, Deary EC, Daskalakis E, Goldschen L, Brunner A, Fathi AT, LeBlanc TW, El-Jawahri A. Coping strategies in patients with acute myeloid leukemia. Blood Adv. 2022 04 12; 6(7):2435-2442. PMID: 34768282; PMCID: PMC9006266.
    Citations: 1     Fields:    Translation:Humans
  19. Kayser S, Kramer M, Martínez-Cuadrón D, Grenet J, Metzeler KH, Sustkova Z, Luskin MR, Brunner AM, Elliott MA, Gil C, Marini SC, Rácil Z, Cetkovsky P, Novak J, Perl AE, Platzbecker U, Stölzel F, Ho AD, Thiede C, Stone RM, Röllig C, Montesinos P, Schlenk RF, Levis MJ. Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. Haematologica. 2022 04 01; 107(4):836-843. PMID: 34348451; PMCID: PMC8968900.
    Citations: 3     Fields:    Translation:Humans
  20. How J, Ren S, Lombardi-Story J, Bergeron M, Foster J, Amrein PC, Brunner AM, Fathi AT, Hock H, Khachatryan A, Kikuchi H, Ng MR, Moran J, Narayan R, Neuberg D, Ramos A, Som T, Vartanian M, Chen YB, Duda DG, Hobbs GS. A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. EJHaem. 2022 May; 3(2):434-442. PMID: 35846042; PMCID: PMC9175677.
    Citations:    
  21. Nardi V, McAfee SL, Dal Cin P, Tsai HK, Amrein PC, Hobbs GS, Brunner AM, Narayan R, Foster J, Fathi AT, Hock H. Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy. Oncologist. 2022 03 04; 27(2):82-86. PMID: 35641210; PMCID: PMC8895729.
    Citations:    Fields:    Translation:Humans
  22. Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. J Natl Compr Canc Netw. 2022 02; 20(2):106-117. PMID: 35130502.
    Citations: 1     Fields:    Translation:Humans
  23. Amrein P, Ballen K, Stevenson K, Brunner A, Hobbs G, Hock H, McAfee S, Moran J, Bergeron M, Foster J, Bertoli C, McGreggor K, Macrea M, Burke M, Behnam T, Som T, Ramos A, Vartanian M, Lombardi Story J, Connolly C, Blonquist T, Neuberg D, Fathi A. Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults. Leuk Lymphoma. 2022 06; 63(6):1428-1435. PMID: 35075985.
    Citations:    Fields:    Translation:Humans
  24. Valtis YK, Stevenson KE, Place AE, Silverman LB, Vrooman LM, Gotti G, Brunner AM, Nauffal M, DeAngelo DJ, Luskin MR. Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. Blood Adv. 2022 01 11; 6(1):72-81. PMID: 34610104; PMCID: PMC8753211.
    Citations: 1     Fields:    Translation:Humans
  25. Mueller SB, Dal Cin P, Le LP, Dias-Santagata D, Lennerz JK, Iafrate AJ, Marble HD, Brunner AM, Weinstock MJ, Luskin MR, De Angelo DJ, Stone RM, Nardi V. t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Adv. 2022 01 08; 6(3):818-827. PMID: 34587239; PMCID: PMC8945303.
    Citations:    Fields:    Translation:Humans
  26. Swoboda DM, Kanagal-Shamanna R, Brunner AM, Cluzeau T, Chan O, Al Ali N, Montalban-Bravo G, Gesiotto QJ, Gavralidis A, Hunter AM, Lee JH, Kuykendall AT, Talati C, Sweet KL, Lancet JE, Padron E, Hussaini M, Song J, Garcia-Manero G, Komrokji RS, Sallman DA. Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia. 2022 04; 36(4):1189-1192. PMID: 34975158.
    Citations: 1     Fields:    Translation:Humans
  27. Mann M, Brunner AM. Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS). Curr Probl Cancer. 2022 02; 46(1):100824. PMID: 34980485; PMCID: PMC8860886.
    Citations: 1     Fields:    Translation:Humans
  28. Vaughn DM, Johnson PC, Jagielo AD, Topping CEW, Reynolds MJ, Kavanaugh AR, Webb JA, Fathi AT, Hobbs G, Brunner A, O'Connor N, Luger S, Bhatnagar B, LeBlanc TW, El-Jawahri A. Factors Associated with Health Care Utilization at the End of Life for Patients with Acute Myeloid Leukemia. J Palliat Med. 2022 05; 25(5):749-756. PMID: 34861118.
    Citations:    Fields:    Translation:Humans
  29. Naranbhai V, Pernat CA, Gavralidis A, St Denis KJ, Lam EC, Spring LM, Isakoff SJ, Farmer JR, Zubiri L, Hobbs GS, How J, Brunner AM, Fathi AT, Peterson JL, Sakhi M, Hambelton G, Denault EN, Mortensen LJ, Perriello LA, Bruno MN, Bertaux BY, Lawless AR, Jackson MA, Niehoff E, Barabell C, Nambu CN, Nakajima E, Reinicke T, Bowes C, Berrios-Mairena CJ, Ofoman O, Kirkpatrick GE, Thierauf JC, Reynolds K, Willers H, Beltran WG, Dighe AS, Saff R, Blumenthal K, Sullivan RJ, Chen YB, Kim A, Bardia A, Balazs AB, Iafrate AJ, Gainor JF. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. J Clin Oncol. 2022 01 01; 40(1):12-23. PMID: 34752147; PMCID: PMC8683230.
    Citations: 12     Fields:    Translation:HumansCells
  30. Yabe M, Omarbekova AZ, Hsu M, May H, Arcila ME, Liu Y, Dogan A, Brunner AM, Nardi V, Hasserjian RP, Klimek VM. TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. Cancers (Basel). 2021 Nov 02; 13(21). PMID: 34771665; PMCID: PMC8582962.
    Citations:    
  31. Nelson AM, Amonoo HL, Kavanaugh AR, Webb JA, Jackson VA, Rice J, Lavoie MW, Fathi AT, Brunner AM, Greer JA, Temel JS, El-Jawahri A, LeBlanc TW. Palliative care and coping in patients with acute myeloid leukemia: Mediation analysis of data from a randomized clinical trial. Cancer. 2021 12 15; 127(24):4702-4710. PMID: 34460937; PMCID: PMC8664993.
    Citations: 1     Fields:    Translation:Humans
  32. Brunner AM, Newcomb RA, Chen YB, Crabbe AM. Case 26-2021: A 49-Year-Old Man with Relapsed Acute Myeloid Leukemia. N Engl J Med. 2021 Aug 26; 385(9):834-843. PMID: 34437787.
    Citations:    Fields:    Translation:Humans
  33. Leiva O, Baker O, Jenkins A, Brunner AM, Al-Samkari H, Leaf RK, Rosovsky RP, Fathi AT, Weitzman J, Bornikova L, Nardi V, Hobbs GS. Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations. JAMA Netw Open. 2021 08 02; 4(8):e2119812. PMID: 34357393.
    Citations: 2     Fields:    Translation:Humans
  34. Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021 12; 35(12):3542-3550. PMID: 34172893; PMCID: PMC8632688.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  35. Chen EC, Li S, Yang J, Zhang ML, Hasserjian R, Chen YB, Brunner AM, DeFilipp Z. Erythroid nuclear dysplasia is associated with inferior outcomes for patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. Leuk Res. 2021 10; 109:106625. PMID: 34062365.
    Citations:    Fields:    Translation:HumansCells
  36. Ott A, Venkataraman V, Badran YR, Goldman R, Spasic S, Vyas DA, Amrein P, McAfee S, Brunner A, Fathi AT, Narayan R. Arsenic toxicity manifesting as profuse watery diarrhea during induction therapy for acute promyelocytic leukemia. Clin Case Rep. 2021 May; 9(5):e04115. PMID: 34026155.
    Citations:    
  37. Sorror ML, Storer BE, Fathi AT, Brunner AM, Gerds AT, Sekeres MA, Mukherjee S, Medeiros BC, Wang ES, Vachhani P, Shami PJ, Peña E, Elsawy M, Adekola KUA, Luger S, Baer MR, Rizzieri D, Wildes T, Koprivnikar J, Smith J, Garrison M, Kojouri K, Leisenring WM, Onstad L, Nyland JE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum F, Estey EH. Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. Blood. 2021 04 28. PMID: 33910230.
    Citations:    Fields:    
  38. Amonoo HL, LeBlanc TW, Kavanaugh AR, Webb JA, Traeger LN, Jagielo AD, Vaughn DM, Elyze M, Longley RM, Fathi AT, Hobbs GS, Brunner AM, O'Connor NR, Luger SM, Gustin JL, Bhatnagar B, Horick NK, El-Jawahri A. Posttraumatic stress disorder symptoms in patients with acute myeloid leukemia. Cancer. 2021 07 15; 127(14):2500-2506. PMID: 33764526.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  39. Kayser S, Hills RK, Langova R, Kramer M, Guijarro F, Sustkova Z, Estey EH, Shaw CM, Rácil Z, Mayer J, Zak P, Baer MR, Brunner AM, Szotkowski T, Cetkovsky P, Grimwade D, Walter RB, Burnett AK, Ho AD, Ehninger G, Müller-Tidow C, Platzbecker U, Thiede C, Röllig C, Schulz A, Warsow G, Brors B, Esteve J, Russell NH, Schlenk RF, Levis MJ. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. Br J Haematol. 2021 03; 192(5):832-842. PMID: 33529373.
    Citations:    Fields:    Translation:HumansCells
  40. El-Jawahri A, LeBlanc TW, Kavanaugh A, Webb JA, Jackson VA, Campbell TC, O'Connor N, Luger SM, Gafford E, Gustin J, Bhatnagar B, Walker AR, Fathi AT, Brunner AM, Hobbs GS, Nicholson S, Davis D, Addis H, Vaughn D, Horick N, Greer JA, Temel JS. Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2021 Feb 01; 7(2):238-245. PMID: 33331857; PMCID: PMC7747042.
    Citations: 11     Fields:    Translation:Humans
  41. Zeidan AM, Komrokji RS, Brunner AM. TIM-3 pathway dysregulation and targeting in cancer. Expert Rev Anticancer Ther. 2021 05; 21(5):523-534. PMID: 33334180.
    Citations: 11     Fields:    Translation:Humans
  42. Brierley CK, Zabor EC, Komrokji RS, DeZern AE, Roboz GJ, Brunner AM, Stone RM, Sekeres MA, Steensma DP. Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. Cancer. 2020 11 01; 126(21):4735-4743. PMID: 32767690.
    Citations:    Fields:    Translation:Humans
  43. Gavralidis A, Brunner AM. Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2020 08; 15(4):294-304. PMID: 32445026; PMCID: PMC8889501.
    Citations: 9     Fields:    Translation:HumansCells
  44. Venkataraman V, Casey KS, Onozato M, Cin PD, Nardi V, Amrein PC, Bergeron MK, Brunner AM, Fathi AT, Foster JE, Moran J, Graubert TA, Hock H, Hunnewell C, Frigault MJ, McAfee S, Hobbs GS. Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. Leukemia. 2020 11; 34(11):3050-3054. PMID: 32678290.
    Citations:    Fields:    Translation:Humans
  45. Kasbekar M, Nardi V, Dal Cin P, Brunner AM, Burke M, Chen YB, Connolly C, Fathi AT, Foster J, Macrae M, McAfee SL, McGregor K, Narayan R, Ramos AY, Som TT, Vartanian M, Friedman RS, Benhadji KA, Hobbs GS. Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. Blood Adv. 2020 07 14; 4(13):3136-3140. PMID: 32649766; PMCID: PMC7362377.
    Citations: 4     Fields:    Translation:Humans
  46. Signorelli J, Lei M, Lam J, Jalbut M, Amrein PC, Fathi AT, Hobbs G, Hock H, McAfee SL, Letourneau AR, Narayan R, Brunner A. Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal Prophylaxis. Clin Lymphoma Myeloma Leuk. 2020 11; 20(11):e883-e889. PMID: 32917574.
    Citations: 1     Fields:    Translation:Humans
  47. Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukherjee S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020 12; 34(12):3149-3160. PMID: 32132655; PMCID: PMC8155811.
    Citations: 15     Fields:    Translation:Humans
  48. Shallis RM, Stahl M, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukhereje S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leuk Lymphoma. 2020 05; 61(5):1220-1225. PMID: 32100599; PMCID: PMC8273667.
    Citations: 3     Fields:    Translation:Humans
  49. Brunner AM. The highs and lows of venetoclax with hypomethylating agents for refractory AML. Leuk Res. 2020 04; 91:106320. PMID: 32089288.
    Citations:    Fields:    Translation:Humans
  50. Nardi V, Ku N, Frigault MJ, Dubuc AM, Tsai HK, Amrein PC, Hobbs GS, Brunner AM, Narayan R, Burke ME, Foster J, Dal Cin P, Maus MV, Fathi AT, Hock H. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 2020 01 14; 4(1):106-111. PMID: 31905241.
    Citations: 8     Fields:    Translation:HumansCells
  51. Garcia JS, Bhatt S, Fell G, Sperling AS, Burgess M, Keshishian H, Yilma B, Brunner A, Neuberg D, Carr SA, Ebert BL, Ballen K, Stone RM, DeAngelo DJ, Medeiros BC, Letai A. Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. Am J Hematol. 2020 03; 95(3):245-250. PMID: 31804723.
    Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
  52. Narayan R, Blonquist TM, Emadi A, Hasserjian RP, Burke M, Lescinskas C, Neuberg DS, Brunner AM, Hobbs G, Hock H, McAfee SL, Chen YB, Attar E, Graubert TA, Bertoli C, Moran JA, Bergeron MK, Foster JE, Ramos AY, Som TT, Vartanian MK, Story JL, McGregor K, Macrae M, Behnan T, Wey MC, Rae J, Preffer FI, Lesho P, Duong VH, Mann ML, Ballen KK, Connolly C, Amrein PC, Fathi AT. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. Cancer. 2020 03 15; 126(6):1264-1273. PMID: 31860140.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  53. Brunner AM, Blonquist TM, DeAngelo DJ, McMasters M, Fell G, Hermance NM, Winer ES, Lindsley RC, Hobbs GS, Amrein PC, Hock HR, Steensma DP, Garcia JS, Luskin MR, Stone RM, Ballen KK, Rosenblatt J, Avigan D, Nahas MR, Mendez LM, McAfee SL, Moran JA, Bergeron M, Foster J, Bertoli C, Manning AL, McGregor KL, Fishman KM, Kuo FC, Baltay MT, Macrae M, Burke M, Behnan T, Wey MC, Som TT, Ramos AY, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg DS, Chen YB, Graubert TA, Fathi AT. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133. PMID: 31837959.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  54. Brunner AM, Steensma DP. Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity. Hematol Oncol Clin North Am. 2020 04; 34(2):379-391. PMID: 32089217.
    Citations:    Fields:    Translation:HumansAnimalsCells
  55. Brunner AM. Acute Myeloid Leukemia: A New Era of Therapies, a New Wave of Toxicities? Acta Haematol. 2020; 143(1):5-6. PMID: 31315110.
    Citations: 1     Fields:    Translation:Humans
  56. Slavin SD, Fenech A, Jankowski AL, Abel GA, Brunner AM, Steensma DP, Fathi AT, DeAngelo DJ, Wadleigh M, Hobbs GS, Amrein PC, Stone RM, Temel JS, El-Jawahri A. Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019 11 01; 125(21):3845-3852. PMID: 31299106; PMCID: PMC6788935.
    Citations: 3     Fields:    Translation:Humans
  57. Taylor J, Haddadin M, Upadhyay VA, Grussie E, Mehta-Shah N, Brunner AM, Louissaint A, Lovitch SB, Dogan A, Fathi AT, Stone RM, Tallman MS, Rampal RK, Neuberg DS, Stevenson KE, Horwitz SM, Lane AA. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019 08 22; 134(8):678-687. PMID: 31243042; PMCID: PMC6706810.
    Citations: 14     Fields:    Translation:HumansCells
  58. Chen EC, Werner L, Hobbs GS, Narayan R, Amrein PC, Fathi AT, Brunner AM. Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. Leuk Lymphoma. 2019 12; 60(12):3058-3062. PMID: 31120366.
    Citations: 2     Fields:    Translation:Humans
  59. Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Rácil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ. Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. Haematologica. 2020 01; 105(1):161-169. PMID: 31004014.
    Citations: 2     Fields:    Translation:Humans
  60. El-Jawahri A, Abel GA, Traeger L, Waldman L, Markovitz N, VanDusen H, Fathi A, Steensma DP, LeBlanc TW, Horick NK, DeAngelo DJ, Wadleigh M, Hobbs G, Foster J, Brunner AM, Amrein P, Stone RM, Temel JS, Greer JA. Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019 10; 33(10):2393-2402. PMID: 30923318.
    Citations: 12     Fields:    Translation:Humans
  61. French CD, Willoughby RE, Pan A, Wong SJ, Foley JF, Wheat LJ, Fernandez J, Encarnacion R, Ondrush JM, Fatteh N, Paez A, David D, Javaid W, Amzuta IG, Neilan AM, Robbins GK, Brunner AM, Hu WT, Mishchuk DO, Slupsky CM. NMR metabolomics of cerebrospinal fluid differentiates inflammatory diseases of the central nervous system. PLoS Negl Trop Dis. 2018 12; 12(12):e0007045. PMID: 30557317; PMCID: PMC6312347.
    Citations: 9     Fields:    Translation:Humans
  62. Brunner AM, Neuberg DS, Wander SA, Sadrzadeh H, Ballen KK, Amrein PC, Attar E, Hobbs GS, Chen YB, Perry A, Connolly C, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, Adamia S, Borger DR, Iafrate A, Graubert TA, Stone RM, Fathi AT. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer. 2019 02 15; 125(4):541-549. PMID: 30422308.
    Citations: 12     Fields:    Translation:Humans
  63. Medford A, Brunner A, Nardi V, Hasserjian R, Carlson J, Choy E. Therapy-Related Erythroleukemia in a Man With Metastatic Ewing Sarcoma: A Clinical Role for Advanced Molecular Diagnostics. JCO Precis Oncol. 2018 Nov; 2:1-6. PMID: 35135116.
    Citations:    Fields:    
  64. Steensma DP, Brunner AM, DeZern AE, Garcia-Manero G, Komrokji RS, Odenike OS, Roboz GJ, Savona MR, Stone RM, Sekeres MA. Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. Cancer. 2018 12 15; 124(24):4601-4609. PMID: 30289970.
    Citations: 5     Fields:    Translation:Humans
  65. Brunner AM, Kim PG, Sadrzadeh H, Drapkin BJ, Sprague KA, Sloan JM, Chai-Ho W, Bhargava P, Pozdnyakova O, Fathi AT. Clustered incidence of adult acute promyelocytic leukemia. Leuk Res. 2018 11; 74:47-50. PMID: 30292128.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  66. Sanford NN, Miao R, Wang H, Goldberg S, Jacobson A, Brunner AM, Cote GM, Yock TI, Ebb DH, Chen YB, Jee KW, Hornicek F, DeLaney TF, Choy E, Chen YL. Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):52-61. PMID: 30165126.
    Citations: 1     Fields:    Translation:Humans
  67. Brunner AM, Weng S, Cronin A, Fathi AT, Habib AR, Stone R, Graubert T, Steensma DP, Abel GA. Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes. Am J Hematol. 2018 09; 93(9):1119-1126. PMID: 30033577.
    Citations: 1     Fields:    Translation:Humans
  68. El-Jawahri A, Nelson-Lowe M, VanDusen H, Traeger L, Abel GA, Greer JA, Fathi A, Steensma DP, LeBlanc TW, Li Z, DeAngelo D, Wadleigh M, Hobbs G, Foster J, Brunner A, Amrein P, Stone RM, Temel JS. Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019 02; 24(2):247-254. PMID: 30139841.
    Citations: 25     Fields:    Translation:Humans
  69. Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018 07 24; 2(14):1765-1772. PMID: 30037803; PMCID: PMC6058241.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  70. Chen EC, Fathi AT, Brunner AM. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. Onco Targets Ther. 2018; 11:3425-3434. PMID: 29928134; PMCID: PMC6003284.
    Citations: 15     
  71. Kim PG, Bridgham K, Chen EC, Vidula MK, Pozdnyakova O, Brunner AM, Fathi AT. Incident adverse events following therapy for acute promyelocytic leukemia. Leuk Res Rep. 2018; 9:79-83. PMID: 29892554; PMCID: PMC5993355.
    Citations: 3     
  72. Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP, Chen YA, Fathi AT, Graubert TA, Brunner AM, Wadleigh M, Stone RM, DeAngelo DJ, Nardi V, Hasserjian RP, Weinberg OK. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825. PMID: 29724895; PMCID: PMC6265642.
    Citations: 31     Fields:    Translation:Humans
  73. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2018 04 24; 2(8):923-932. PMID: 29685952.
    Citations: 34     Fields:    Translation:HumansCells
  74. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biol Blood Marrow Transplant. 2018 08; 24(8):1754-1758. PMID: 29649620.
    Citations:    Fields:    Translation:Humans
  75. Brunner AM. No Mutation Left Behind: The Impact of Reporting Recurrent Genetic Abnormalities on Outcomes of Patients with Acute Myeloid Leukemia. Acta Haematol. 2018; 139(2):128-130. PMID: 29444505.
    Citations:    Fields:    Translation:Humans
  76. Brunner AM, Graubert TA. Genomics in childhood acute myeloid leukemia comes of age. Nat Med. 2018 01 09; 24(1):7-9. PMID: 29315296.
    Citations: 3     Fields:    Translation:Humans
  77. Brunner AM, Steensma DP. Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches. Clin Adv Hematol Oncol. 2018 Jan; 16(1):56-66. PMID: 29741506; PMCID: PMC6629038.
    Citations: 6     Fields:    Translation:Humans
  78. Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH. Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA Oncol. 2017 12 01; 3(12):1675-1682. PMID: 28880971.
    Citations: 32     Fields:    Translation:Humans
  79. DeAngelo DJ, Brunner AM, Werner L, Avigan D, Fathi AT, Sperling AS, Washington A, Stroopinsky D, Rosenblatt J, McMasters M, Luptakova K, Wadleigh M, Steensma DP, Hobbs GS, Attar EC, Amrein PC, Ebert BL, Stone RM, Ballen KK. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261. PMID: 29119643; PMCID: PMC6290473.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  80. Sanford NN, Martin AM, Brunner AM, Cote GM, Choy E, DeLaney TF, Aizer AA, Chen YL. Secondary Acute Leukemia in Sarcoma Patients: A Population-Based Study. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):687-694. PMID: 29413281.
    Citations: 1     Fields:    Translation:Humans
  81. Wander SA, Hasserjian RP, Oduro K, Glomski K, Nardi V, Cote GM, Graubert TA, Brunner AM, Chen YA, Fathi AT. Combined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia. JCO Precis Oncol. 2017 Nov; 1:1-7. PMID: 35172484.
    Citations:    Fields:    
  82. Brunner AM, Blonquist TM, Hobbs GS, Amrein PC, Neuberg DS, Steensma DP, Abel GA, Fathi AT. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017 Oct 24; 1(23):2032-2040. PMID: 29296849.
    Citations: 17     Fields:    
  83. Fathi AT, Blonquist TM, Hernandez D, Amrein PC, Ballen KK, McMasters M, Avigan DE, Joyce R, Logan EK, Hobbs G, Brunner AM, Joseph C, Perry AM, Burke M, Behnan T, Foster J, Bergeron MK, Moran JA, Ramos AY, Som TT, Rae J, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Levis MJ. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer. 2018 01 15; 124(2):306-314. PMID: 28960265; PMCID: PMC8167813.
    Citations: 12     Fields:    Translation:Humans
  84. Assuncao BMBL, Handschumacher MD, Brunner AM, Yucel E, Bartko PE, Cheng KH, Campos O, Fathi AT, Tan TC, Scherrer-Crosbie M. Acute Leukemia is Associated with Cardiac Alterations before Chemotherapy. J Am Soc Echocardiogr. 2017 Nov; 30(11):1111-1118. PMID: 28927558.
    Citations: 9     Fields:    Translation:Humans
  85. Qualls D, Sullivan A, Li S, Brunner AM, Collier K, Hochberg E, Armand P, Batchelor TT, Chen YB, DeFilipp Z. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):884-888. PMID: 28870642.
    Citations: 7     Fields:    Translation:Humans
  86. Jalbut MM, Brunner AM, Amrein PC, Ballen KK, Hobbs GS, Perry AM, Joseph CP, Fathi AT. Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):988-991. PMID: 28792269; PMCID: PMC6197051.
    Citations: 1     Fields:    Translation:HumansCells
  87. Perry AM, Brunner AM, Zou T, McGregor KL, Amrein PC, Hobbs GS, Ballen KK, Neuberg DS, Fathi AT. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study. Cancer. 2017 Jul 01; 123(13):2561-2569. PMID: 28464280; PMCID: PMC5474167.
    Citations: 16     Fields:    Translation:Humans
  88. Brunner AM, Stock W. Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML. Oncology (Williston Park). 2017 Mar 15; 31(3):190, 192. PMID: 28299756.
    Citations:    Fields:    Translation:Humans
  89. Upadhyay VA, Brunner AM, Fathi AT. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions. Pharmacol Ther. 2017 Sep; 177:123-128. PMID: 28315358.
    Citations: 8     Fields:    Translation:HumansAnimals
  90. Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, Sun L, Upadhyay V, Hamdan A, Brunner AM, Gansner JM, Viswanathan S, Kaufman RM, Uhl L, Stowell CP, Dzik WH, Makar RS. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017 Apr; 4(4):e157-e164. PMID: 28259520.
    Citations: 99     Fields:    Translation:Humans
  91. Kovach AE, Brunner AM, Fathi AT, Chen YB, Hasserjian RP. Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation. Am J Clin Pathol. 2017 Jan 01; 147(1):50-59. PMID: 28108471.
    Citations:    Fields:    Translation:Humans
  92. Fathi AT, Wander SA, Blonquist TM, Brunner AM, Amrein PC, Supko J, Hermance NM, Manning AL, Sadrzadeh H, Ballen KK, Attar EC, Graubert TA, Hobbs G, Joseph C, Perry AM, Burke M, Silver R, Foster J, Bergeron M, Ramos AY, Som TT, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Chen YB. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017 04; 102(4):719-727. PMID: 28034990.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  93. Brunner AM, Li S, Fathi AT, Wadleigh M, Ho VT, Collier K, Connolly C, Ballen KK, Cutler CS, Dey BR, El-Jawahri A, Nikiforow S, McAfee SL, Koreth J, Deangelo DJ, Alyea EP, Antin JH, Spitzer TR, Stone RM, Soiffer RJ, Chen YB. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504. PMID: 27434660; PMCID: PMC5083189.
    Citations: 58     Fields:    Translation:HumansCells
  94. Brunner AM, Steensma DP. Myelodysplastic syndrome associated with acquired beta thalassemia: "BTMDS". Am J Hematol. 2016 08; 91(8):E325-7. PMID: 27121565; PMCID: PMC4947000.
    Citations: 1     Fields:    Translation:Humans
  95. Brunner AM, Fathi AT, Chen YB. Life after transplant: are we becoming high maintenance in AML? Bone Marrow Transplant. 2016 Nov; 51(11):1423-1430. PMID: 27322850.
    Citations: 3     Fields:    Translation:Humans
  96. Kim PG, Suh J, Adelman MW, Oduro K, Williams E, Brunner AM, Kuter DJ. Pure White Cell Aplasia and Necrotizing Myositis. Case Rep Hematol. 2016; 2016:4161679. PMID: 27073704; PMCID: PMC4814688.
    Citations: 2     
  97. Platt MY, Fathi AT, Borger DR, Brunner AM, Hasserjian RP, Balaj L, Lum A, Yip S, Dias-Santagata D, Zheng Z, Le LP, Graubert TA, Iafrate AJ, Nardi V. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Mol Diagn. 2015 Nov; 17(6):661-8. PMID: 26331834; PMCID: PMC4630164.
    Citations: 10     Fields:    Translation:Humans
  98. Brunner AM, Hobbs G, Jalbut MM, Neuberg DS, Fathi AT. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. Leuk Lymphoma. 2016 May; 57(5):1197-200. PMID: 26155828; PMCID: PMC4943877.
    Citations: 10     Fields:    Translation:HumansPHPublic Health
  99. Huck A, Pozdnyakova O, Brunner A, Higgins JM, Fathi AT, Hasserjian RP. Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia. Leuk Res. 2015 Oct; 39(10):1034-40. PMID: 26220865; PMCID: PMC5764101.
    Citations: 3     Fields:    Translation:Humans
  100. El-Jawahri AR, Abel GA, Steensma DP, LeBlanc TW, Fathi AT, Graubert TA, DeAngelo DJ, Wadleigh M, Ballen KK, Foster JE, Attar EC, Amrein PC, Brunner AM, Stone RM, Temel JS. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8. PMID: 25926135; PMCID: PMC4418225.
    Citations: 43     Fields:    Translation:Humans
  101. Jalbut MM, Sohani AR, Dal Cin P, Hasserjian RP, Moran JA, Brunner AM, Fathi AT. Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype. Leuk Res Rep. 2015; 4(1):28-30. PMID: 25973391; PMCID: PMC4421110.
    Citations:    
  102. Movassaghian M, Brunner AM, Blonquist TM, Sadrzadeh H, Bhatia A, Perry AM, Attar EC, Amrein PC, Ballen KK, Neuberg DS, Fathi AT. Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis. Leuk Lymphoma. 2015 Jun; 56(6):1698-703. PMID: 25213180.
    Citations: 26     Fields:    Translation:Humans
  103. Brunner AM, Blonquist TM, Sadrzadeh H, Perry AM, Attar EC, Amrein PC, Ballen KK, Chen YB, Neuberg DS, Fathi AT. Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res. 2014 Jul; 38(7):773-80. PMID: 24793731.
    Citations: 5     Fields:    Translation:HumansCells
  104. Nokoff N, Brunner AM, Linakis JG, Amanullah S. Presentation to either the pediatric emergency department or primary care clinic for acute illness: the caregivers' perspective. Pediatr Emerg Care. 2014 Mar; 30(3):146-50. PMID: 24583577.
    Citations: 3     Fields:    Translation:HumansPHPublic Health
  105. Yeh AC, Brunner AM, Spitzer TR, Chen YB, Coughlin E, McAfee S, Ballen K, Attar E, Caron M, Preffer FI, Yeap BY, Dey BR. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014 May; 20(5):730-4. PMID: 24530972.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  106. Graubert TA, Brunner AM, Fathi AT. New molecular abnormalities and clonal architecture in AML: from reciprocal translocations to whole-genome sequencing. Am Soc Clin Oncol Educ Book. 2014; e334-40. PMID: 24857122.
    Citations: 5     Fields:    Translation:Humans
  107. Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE, Hammerman PS. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol. 2013 Nov; 8(11):1434-7. PMID: 24128713.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  108. Brunner AM, Kim HT, Coughlin E, Alyea EP, Armand P, Ballen KK, Cutler C, Dey BR, Glotzbecker B, Koreth J, McAfee SL, Spitzer TR, Soiffer RJ, Antin JH, Ho VT, Chen YB. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1374-80. PMID: 23791626.
    Citations: 36     Fields:    Translation:Humans
  109. Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, Amrein PC, McAfee SL, Chen YB, Neuberg DS, Fathi AT. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol. 2013 Aug; 88(8):642-6. PMID: 23619915.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  110. Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen YB, Neuberg DS, Fathi AT. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013 Jul 15; 119(14):2620-9. PMID: 23625575.
    Citations: 19     Fields:    Translation:Humans
  111. Brunner AM, Henn CM, Drewniak EI, Lesieur-Brooks A, Machan J, Crisco JJ, Ehrlich MG. High dietary fat and the development of osteoarthritis in a rabbit model. Osteoarthritis Cartilage. 2012 Jun; 20(6):584-92. PMID: 22353745.
    Citations: 22     Fields:    Translation:Animals
  112. Connell NT, Brunner AM, Kerr CA, Schiffman FJ. Splenosis and sepsis: The born-again spleen provides poor protection. Virulence. 2011 Jan-Feb; 2(1):4-11. PMID: 21224728.
    Citations: 10     Fields:    Translation:HumansAnimals
  113. Brunner A, Mitsutani CY, de Araújo Peres C. Comparative ultrastructure of late rabbit-embryo erythroid cells in liver and peripheral blood. Am J Hematol. 1977; 2(3):227-36. PMID: 596367.
    Citations: 1     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Brunner's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (300)
Explore
_
Co-Authors (138)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.